Ozurdex (dexamethasone intravitreal implant) / AbbVie - LARVOL DELTA

A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China (clinicaltrials.gov) - P=N/A | N=110 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed • Real-world evidence • Diabetic Macular Edema • Ophthalmology

The Role of Adding Intravitreal Dexamethasone Implant to the Standard Management of Serpiginous Choroiditis for Achieving Rapid Remission: A Case Report. (PubMed, Int Med Case Rep J) - "To prevent systemic adverse effects and obtain rapid control of serpiginous lesions, as necessary in the case presented, local therapy using a dexamethasone intravitreal implant may be considered as a complement to systemic treatment...The patient was started oral prednisolone 0.5 mg/kg tapering; however, because the patient would be traveling for three weeks, the systemic oral steroid with an intravitreal dexamethasone implant in each eye...After starting Azathioprine, disease activity was suppressed for six months without relapsing. This case raises a question about the benefit of combined therapy for quick vision restoration, inhibiting further destruction of outer retinal layers during the management of acute attack and reduction of overall systemic steroids dose together with its complications versus the risk of local steroids administration and cost-effectiveness. Additional research is required to validate this finding."

Journal • Infectious Disease • Ocular Inflammation • Ophthalmology • Uveitis

STAMP: Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification (clinicaltrials.gov) - P4 | N=16 | Completed | Sponsor: Bay Area Retina Associates | Recruiting ➔ Completed | N=32 ➔ 16

Enrollment change • Trial completion • Cataract • Diabetic Macular Edema • Ophthalmology

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma (clinicaltrials.gov) - P2 | N=28 | Active, not recruiting | Sponsor: University of Rochester | Trial completion date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

OXEYE: Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema (clinicaltrials.gov) - P2 | N=3 | Completed | Sponsor: Oxular Limited | Active, not recruiting ➔ Completed

Trial completion • Diabetic Macular Edema • Ophthalmology

Genicular and Anterior Femoral Cutaneous Nerve Blocks for Total Knee Arthroplasty (clinicaltrials.gov) - P4 | N=244 | Recruiting | Sponsor: Hospital for Special Surgery, New York | Trial primary completion date: May 2025 ➔ Dec 2025

Trial primary completion date • Musculoskeletal Diseases • Orthopedics • Pain

Clinical research of portable detective technology fo aqeous humor on retianl vein occlusion secondary to macular edema (ChiCTR) - P=N/A | N=56 | Not yet recruiting | Sponsor: Shenzhen Eye Hospital; Shenzhen Eye Hospital

New trial • Macular Edema • Ophthalmology • Retinal Vein Occlusion • CXCL8

Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections (clinicaltrials.gov) - P=N/A | N=200 | Recruiting | Sponsor: Rigshospitalet, Denmark | Trial completion date: Sep 2025 ➔ Jan 2026 | Trial primary completion date: Jul 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date

Are dexamethasone implants a safe and effective breakthrough in uveitis treatment? A systematic review and meta-analysis. (PubMed, Steroids) - "Dexamethasone implants offer clinically significant benefits, resulting in substantial reductions in central retinal thickness, improvements in visual acuity, and effective control of inflammation in patients with uveitis."

Journal • Retrospective data • Cataract • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis

Time-in-Range Analysis of Responses after Intravitreal Dexamethasone Therapy in Eyes with Diabetic Macular Edema. (PubMed, Ophthalmol Sci) - P3 | "The MEAD trial comprised two 3-year randomized, multicenter, sham-controlled, phase III clinical studies that evaluated the efficacy and safety of dexamethasone intravitreal implant (DEX-I) in patients with diabetic macular edema...These results suggest that patients treated with dexamethasone experience a longer time with clinically meaningful outcomes than with sham, such as being able to drive or regaining normal structural retinal features. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders

Baseline factors affecting diabetic macular oedema resolution after intravitreal dexamethasone implant treatment: post hoc analysis of the MEAD study. (PubMed, BMC Ophthalmol) - P3 | "Treatment with DEX shortened the time to DME resolution compared with sham. Higher CRT was associated with longer time to DME resolution. These findings may influence therapeutic decisions."

Journal • Retrospective data • Diabetic Macular Edema • Diabetic Retinopathy • Macular Edema • Ophthalmology • Retinal Disorders

Impact of the Dexamethasone Implant on Slowing Diabetic Retinopathy Progression: Post Hoc Analysis of the MEAD Study. (PubMed, Retina) - "This post hoc analysis of MEAD study data showed that DEX treatment may potentially have a positive impact on DR by reducing disease severity and slowing progression in DR patients with central DME."

Journal • Retrospective data • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Subconjunctival dexamethasone implant (Ozurdex) for peripheral ulcerative keratitis. (PubMed, Am J Ophthalmol Case Rep) - "Systemic immunosuppressive treatment with steroids and methotrexate resulted in complete healing. No scleral melt or ocular hypertension was noted 11 months after the first injection. Subconjunctival dexamethasone implant injection can be a well-tolerated treatment option for peripheral ulcerative keratitis."

Journal • Cardiovascular • Glaucoma • Keratitis • Ocular Inflammation • Ophthalmology

Early combined conbercept and dexamethasone implant therapy for diabetic macular edema. (PubMed, Int Ophthalmol) - "Early combined therapy with dexamethasone implant (Ozurdex) and Conbercept injections offers significant clinical benefits for the treatment of DME during the initial three months of treatment."

Clinical • Journal • Cataract • Diabetic Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders

Innovative surgical approach for persistent macular holes: the role of plasma rich in growth factors technology (SOE 2025) - "An intravitreal injection of a dexamethasone implant (Ozurdex®) was initially attempted without any benefit. This case demonstrates the effectiveness and safety of PRGF when used as an adjunctive treatment for persistent MH. While the use of PRGF in retina surgery shows promise, further research is needed to establish its efficacy, optimal concentration, timing, and mode of delivery."

Ophthalmology • Retinal Disorders

Eight-year follow-up of iluvien treated Diabetic Macular Edema (DME) patients: long term outcomes (SOE 2025) - "Iluvien may have an effect on DME beyond 3 years, as 33% (n=3) of our cohort stopped anti-VEGF and ozurdex injections 8 years after their 1st Iluviens. whilst 11% (n=1) of our cohort needed a 2nd Iluvein. 22% of patients (n=2) stayed completely intravitreal injection free at year 8."

Clinical • Diabetic Macular Edema • Glaucoma • Ophthalmology

Vogt-Koyanagi-Harada disease revealed by uveitis: a case report (SOE 2025) - "The probable form of VKH disease is relatively rare, but it should be considered when characteristic ocular signs are observed in the fundus. The early treatment is crucial for a favorable prognosis."

Case report • Clinical • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis

Presentation and outcomes of acute bacterial endophthalmitis secondary to Intravitreal Dexamethasone implant (SOE 2025) - "Endophthalmitis in the setting of Ozurdex results in variable visual outcomes. The most common causative organism is Staphylococcus epidermidis. Prompt treatment with broad-spectrum intravitreal antibiotics is highly recommended."

Diabetic Macular Edema • Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology

Incidence and risk factors of ocular hypertension following ıntravitreal dexamethasone implantation: the role of baseline intraocular pressure. (PubMed, Int Ophthalmol) - "Intravitreal Ozurdex implantation is associated with a significant increase in IOP, necessitating close monitoring. Higher baseline IOP and male gender were identified as major risk factors. While the majority of cases were successfully managed with topical therapy, a small proportion required surgical intervention. Further research is warranted to improve risk stratification and optimize management strategies."

Journal • Retrospective data • Cardiovascular • Diabetic Macular Edema • Glaucoma • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Dexamethasone intravitreal implant combines with VEGFR fusion protein versus VEGFR fusion protein alone for Diabetic Macular Edema: a multicentre, randomized, open-label clinical trial (ChiCTR) - P2 | N=98 | Completed | Sponsor: The Second Affiliated Hospital of Air Force Military Medical University,Chinese People’s Liberation Army; The Second Affiliated Hospital of Air Forc

New P2 trial • Diabetic Macular Edema • Ophthalmology

Delayed-Onset Endophthalmitis After Intravitreal Dexamethasone Implantation. (PubMed, J Vitreoretin Dis) - "Purpose: To present a series of cases of acute endophthalmitis after intravitreal (IVT) sustained-release dexamethasone implantation (Ozurdex) with an unusually delayed onset... Delayed-onset acute endophthalmitis after dexamethasone implantation represents a clinical challenge, potentially occurring up to weeks after the injection. Sustained suspicion for endophthalmitis is warranted given that cases may present beyond what is typical for postinjection endophthalmitis."

Journal • Ocular Infections • Ocular Inflammation • Ophthalmology

Predictive Value of Optical Coherence Tomography Biomarkers in Patients with Persistent Diabetic Macular Edema Undergoing Cataract Surgery Combined with a Dexamethasone Intravitreal Implant. (PubMed, Bioengineering (Basel)) - " The administration of DEX-I for DME refractory to anti-VEGF treatment in patients undergoing cataract surgery promoted functional improvements persisting longer than the anatomical ones. Patients presenting with DRIL, disrupted EZ, and higher CST at baseline may be better candidates for the combination of DEX-I and cataract surgery."

Biomarker • Journal • Cataract • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders

Dexamethasone intravitreal implant monotherapy in naive patients with macular edema secondary to retinal vein occlusion: long term follow-up retrospective cohort study. (PubMed, Int J Ophthalmol) - "Intravitreal dexamethasone monotherapy is an effective and safe treatment option for the treatment-naive RVO-ME patients in the long-term follow-up."

Journal • Monotherapy • Retrospective data • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

YAG Laser-Assisted Fragmentation of Dexamethasone Implants in the Anterior Chamber. (PubMed, Retina) - "Spontaneous migration of the dexamethasone intravitreal implant into the anterior chamber can occur in patients with aphakia, prior pars plana vitrectomy, or compromised capsular support. Timely intervention using Nd:yag laser can effectively fragment the dexamethasone implant, mitigating the risk of corneal endothelial damage and preserving visual function. In this cohort Nd:yag laser appeared a safe and effective treatment option for managing anterior chamber migration of the dexamethasone intravitreal implant, avoiding the need for more invasive surgical techniques or temporary non-invasive techniques."

Journal • Cataract • Macular Edema • Ophthalmology

Subconjunctival dexamethasone implant (Ozurdex®) in the management of refractory Non-Infectious anterior scleritis. (PubMed, J Ophthalmic Inflamm Infect) - "SDI may be a safe and effective therapeutic option for resistant non-infectious anterior scleritis."

Journal • Cardiovascular • Glaucoma • Immunology • Infectious Disease • Inflammatory Arthritis • Ocular Infections • Ocular Inflammation • Ophthalmology • Rare Diseases • Rheumatoid Arthritis • Rheumatology • Scleritis • Vasculitis